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ABSTRACT
Objective: Our prespecified dose-response analyses of A Very Early Rehabilitation Trial (AVERT)
aim to provide practical guidance for clinicians on the timing, frequency, and amount of mobiliza-
tion following acute stroke.
Methods: Eligible patients were aged$18 years, had confirmed first (or recurrent) stroke, and were
admitted to a stroke unit within 24 hours of stroke onset. Patients were randomized to receive very
early and frequent mobilization, commencing within 24 hours, or usual care. We used regression
analyses and Classification and Regression Trees (CART) to investigate the effect of timing and dose
of mobilization on efficacy and safety outcomes, irrespective of assigned treatment group.
Results: A total of 2,104patientswere enrolled, ofwhom2,083 (99.0%)were followedupat3months.
We found a consistent pattern of improved odds of favorable outcome in efficacy and safety outcomes
with increased daily frequency of out-of-bed sessions (odds ratio [OR] 1.13, 95%confidence interval [CI]
1.09 to1.18,p,0.001), keeping time to firstmobilization andmobilization amount constant. Increased
amount (minutes per day) ofmobilization reduced the odds of a goodoutcome (OR0.94, 95%CI0.91 to
0.97, p , 0.001). Session frequency was the most important variable in the CART analysis, after
prognostic variables age and baseline stroke severity.
Conclusion: These data suggest that shorter, more frequent mobilization early after acute stroke
is associated with greater odds of favorable outcome at 3 months when controlling for age and
stroke severity.
Classification of evidence: This study provides Class III evidence that shorter, more frequent early
mobilization improves the chance of regaining independence after stroke. Neurology®2016;86:1–8
GLOSSARY
AVERT 5 A Very Early Rehabilitation Trial; CART 5 Classification and Regression Tree; CI 5 confidence interval; IQR 5
interquartile range; mRS 5 modified Rankin Scale; NIHSS 5 NIH Stroke Scale; OR 5 odds ratio; ROC 5 receiver operating
characteristic; rtPA 5 recombinant tissue plasminogen activator; SAE 5 serious adverse event; TTFM 5 time from stroke
onset to first mobilization out of bed; VEM 5 very early mobilization.
In our primary intention-to-treat analysis for A Very Early Rehabilitation Trial (AVERT), we
reported that patients randomized to usual care had greater odds of a favorable outcome (mod-
ified Rankin Scale [mRS] score 0–2) at 3 months compared to those receiving the very early
mobilization (VEM) protocol.1 However, a recommendation of “usual care” is of limited value
to clinicians seeking guidance, as usual care was not standardized and mobilization often com-
menced within 24 hours of stroke. Importantly, “early” does not encapsulate all aspects of the
interventions delivered in this trial. The VEM protocol was earlier, more frequent, and higher
amounts of out-of-bed activity,2 a “complex intervention,”3 which was consistent with practices
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associated with better outcome in Norway.4
Greater amounts of physical training post-
stroke is associated with improved outcomes
(without harm) in a number of meta-
analyses,5,6 and many guidelines recommend
increasing training dose. Increased frequency,
a critical intervention characteristic, was sup-
ported by 2 lines of evidence. Exercise benefits
in sedentary adults, accumulated in multiple,
short bouts, appear equivalent to a single,
longer bout,7,8 and bursts of training appear
highly suited to acute stroke patients. Further,
frequent repetition of training (distributed
practice) is associated with improved motor
learning after stroke.9,10 In AVERT, all inter-
ventions were carefully recorded, thus allow-
ing a detailed investigation of dose response.
Our aim for these prespecified dose-response
analyses11 is to provide practical guidance for
clinicians.
The trial is registered with the Australia
and New Zealand Clinical Trial Registry
(ACTRN12606000185561).
METHODS Detailed methods are described elsewhere.1,11 In
brief, AVERT, conducted in 56 stroke units in 5 countries, is a
pragmatic, parallel-group, randomized controlled trial. Patients
with ischemic or hemorrhagic stroke, admitted within 24 hours
of onset, were eligible. Patients with early deterioration, another
serious illness, unstable coronary conditions, not rousable to
voice, or failing physiologic screening criteria were excluded.
Patients or their nominated representative provided written
consent. Randomization was blocked, balanced by site, and
stratified by stroke severity. All trial personnel were masked to
group, except the intervention monitor.
Standard protocol approvals, registrations, and patient
consents. Ethical approval was obtained from relevant site insti-
tutional boards.
Procedures. Patients were randomized to receive either usual
care or frequent out-of-bed activity (mobilization) in addition
to usual care (VEM).1,11 VEM patients commenced
mobilization within 24 hours of stroke and trained
physiotherapy and nursing staff helped them continue task-
specific out-of-bed activity, targeting recovery of active sitting,
standing, and walking activity, at a frequency and intensity
(amount) guided by an intervention protocol. Functional
ability at baseline, monitored daily and adjusted with recovery,
guided the intervention dose with 4 titrations specified. For
example, in low arousal, dependent patients (level 1), active
sitting with assistance was the mobilization target, with each
session lasting a minimum of 10 and maximum of 30 minutes.
With higher-functioning patients (level 4), standing and walking
were likely targets, each session again lasting a minimum of
10 minutes with no restricted maximum (patient-dependent).
The frequency of sessions per day also varied according to
functional level. Importantly, passive sitting (resting in a chair)
was not classified as a VEM mobilization activity and sitting for
more than 50 minutes at one time was discouraged. Intervention
lasted 14 days or until discharge, whichever was sooner.
Physiotherapists and nurses, with separate intervention targets,
worked together to deliver the intervention dose. All
mobilization activities were recorded online.
Outcome measures. Our primary outcome was a favorable out-
come on the modified Rankin Scale (mRS 0–2) at 3 months
poststroke.1 Secondary outcomes were time (days) to achieve
unassisted walking over 50 meters, the proportion of patients
achieving unassisted walking by 3 months, death, and the num-
ber of serious adverse events (SAEs) at 3 months. Immobility-
related SAEs (deep venous thrombosis, pulmonary emboli,
pressure sores, chest infections, urinary tract infections) and
neurologic SAEs (stroke progression, recurrent stroke) were
examined separately.
Dose measures. The dose-response analyses examine the 3 main
characteristics of dose: (1) time from stroke onset to first
mobilization out of bed (TTFM, hours), (2) median number of
out-of-bed sessions per patient per day (frequency), and (3)
median minutes of out-of-bed activity per patient per day (daily
amount). Total minutes of out-of-bed activity over the
intervention period (total amount) accounts for varying lengths
of hospital stay.
Nurses recorded type of activity and time of the day each
activity began, but not minutes, as this was not routine practice.
Physiotherapists recorded activity type, time the activity began,
and total out-of-bed activity time (minutes), consistent with their
routine practice. Consequently, daily amount (minutes) and total
amount (minutes) of out-of-bed activity reflect physiotherapy
data alone, while TTFM and frequency of mobilizations is
derived from both nurse and physiotherapist data. Episodes of sit-
ting, standing, or walking activity separated from another episode
of activity by .5 minutes of rest (e.g., in a chair) constituted 2
separate mobilizations. Active time (minutes), e.g., practicing sit-
to-stand from the chair, was recorded by the physiotherapist.
Statistical analysis. These dose-response analyses repeat our
major primary and secondary analyses1 with dose characteristics
(TTFM, frequency, daily amount, total amount) as independent
variables, and were prespecified in our statistical analysis plan.11
To avoid excessive collinearity between daily amount and total
amount, we tested 2 separate models, adjusted for age and
baseline stroke severity (NIH Stroke Scale [NIHSS]), for all
analyses, as follows:
1. Model 1: TTFM, median daily number of out-of-bed sessions
(frequency), median daily out-of-bed session time (in 5-
minute increments).
2. Model 2: TTFM, median daily number of out-of-bed sessions
(frequency), total minutes in out-of-bed activity over the
intervention period (in 5-minute increments).
The primary analysis, with favorable outcome (mRS 0–2) at 3
months as the dependent variable, was conducted using binary
logistic regression models.
The dose effect on the odds of achieving unassisted walking
by 3 months was investigated using binary logistic regression anal-
yses (effect sizes: adjusted odds ratios [ORs] and 95% confidence
intervals [CIs]) while the time (days) to achieve unassisted walk-
ing (censored at 3 months) was assessed using Cox regression
analyses (adjusted hazard ratios with 95% CIs).
We analyzed mortality outcomes using binary logistic regres-
sion with death at 3 months (mRS 6) as the dependent variable
(effect sizes: adjusted ORs with 95% CIs). We investigated dose
effect on counts of SAEs using negative binomial regression
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(effect sizes: adjusted incidence rate ratios with 95% CIs).
Immobility-related and neurologic SAEs were analyzed
separately.
We used Classification and Regression Tree (CART)
advanced analysis (Salford Predictive Modeler Software Suite ver-
sion 7, Salford Systems, San Diego, CA) to further investigate the
complex interactions between patient and dose characteristics and
favorable outcome. CART is a binary partitioning statistical
method that starts with the total sample and, in a stepwise man-
ner, splits the sample into subsamples that are homogenous with
respect to a defined outcome.12 The input variable that achieves
the most effective split is dichotomized by automated analysis at
an optimal threshold, maximizing the homogeneity within, and
separation between, resulting subgroups. To maximize model
performance (assessed by area under the receiver operating char-
acteristic [ROC] curve), a 10-fold internal cross-validation, where
data are randomly divided into 10 groups with 9 used to build the
model (training) and 1 used to validate (testing), is performed. In
addition to the classification tree, CART numerically ranks each
input used to build the tree by relative importance.
Our CART1 (figure 1) analysis included all prespecified sub-
group variables1 (age, NIHSS, stroke type, recombinant tissue
plasminogen activator [rtPA] treatment), group allocation, and
the 3 dose characteristics (TTFM, frequency, and daily amount).
We explored the relative importance of each variable to achieving
a favorable outcome (mRS 0–2). CART2 (figure e-1 on the
Neurology® Web site at Neurology.org) was used to investigate
multidimensional relationships between dose characteristics alone
and favorable outcome.
RESULTS Between July 18, 2006, and October 16,
2014, we randomly assigned 2,104 patients to VEM
(n 5 1,054) and usual care (n 5 1,050), with 2,083
(99%) patients followed to the primary 3-month
endpoint. This group constitutes the dataset for all
analyses in this article. In total, 25% were over 80
years of age, few were disabled prior to stroke, more
than 43% of patients experienced a moderate to
severe stroke (NIHSS . 7), and 12% were
diagnosed with intracerebral hemorrhage (table 1).
A total of 1,584 patients (75%) had no disability
(premorbid mRS 0) prior to stroke, a further 519
(24%) had slight disability (mRS 1–2), and 1,833
(87%) could walk without aids. The median
(interquartile range [IQR]) time to first
mobilization was 20.2 hours (14.7–23.8), while
1,588 (75%) participants commenced out-of-bed
activity within 24 hours of stroke (table 2).
Greater TTFM was associated with a reduced odds
of favorable outcome (0.99, 0.98–1.00, p 5 0.036;
table 3). In model 1 (favorable outcome), the effect
of TTFM was adjusted for median daily number of
sessions (frequency), median daily minutes (daily
amount), age, and baseline NIHSS. In this example,
the significant effect for TTFM on the odds of a favor-
able outcome should be interpreted as follows: for 2
patients of similar age and stroke severity, receiving a
similar frequency and daily amount of out-of-bed
activity, the patient who starts mobilization earlier
has improved odds of a favorable outcome.
For efficacy outcomes, favorable outcome (mRS 0–2)
and walking by 3 months, we found a similar pattern of
association with each of the dose characteristics, and all
associations were significant (table 3). In model 1,
TTFM, frequency, and daily amount all significantly
influenced the odds of a favorable outcome. Keeping
TTFM and frequency constant, every extra 5 minutes
of out-of-bed activity per day reduced the odds of a
favorable outcome. Increasing the frequency of sessions
improved the odds of favorable outcome by 13% (95%
CI 9–18 p, 0.001) and improved the odds of walking
50 meters unassisted by 66% (95% CI 53–80, p ,
0.001) when TTFM and daily amount were kept con-
stant. This pattern was similar in model 2.
When examining associations with intervention
characteristics and death, increasing session frequency
was the only characteristic that reduced the odds of
death by approximately 20% (table 4). Nonfatal SAEs
showed less consistent associations between dose char-
acteristics and outcome. TTFM was not significant in
any model, but frequency and amount were (table 4).
Given the relatively few immobility and neurologic
SAEs, these results should be viewed with caution.
In CART1 (figure 1), including TTFM, fre-
quency and daily amount, age, NIHSS, stroke sub-
type, rtPA treatment, and randomization group, we
found good to excellent performance, with a training
ROC of 0.78 and a testing ROC of 0.77. The relative
contribution of variables to the model showed initial
stroke severity (NIHSS), a known predictor of recov-
ery, was most important (100%), followed by session
frequency (39.2%), age (32.4%), TTFM (10.5%),
and daily amount (2.7%). Treatment group was not
an important discriminator.
Younger patients (#76.3 years) and those with
low NIHSS score (#7.5) had high probability of a
favorable outcome (78.2%). Those with NIHSS
score .7.5 showed low (21.3%) probability of
achieving little to no disability (mRS 0–2). The influ-
ence of intervention characteristics becomes evident
as we move farther down the tree. For example, at
terminal node 4 (figure 1), patients between 76.3 and
86.1 years, with an NIHSS score .4.5 (but #7.5),
showed greater probability of a favorable outcome
(63.6%) if they received no more than 13.5 minutes
per day distributed across frequent (short) sessions.
Frequency again split the tree for terminal nodes 5
and 6, indicating that more frequent sessions to
achieve a higher dose (.13.5 minutes per day) was
associated with greater odds of a good outcome.
CART2 (figure e-1) explores the influence of dose
variables on outcome. Further exploration of CART1
large terminal nodes 1 (younger age) and 8 (more
severe stroke) are shown in figures e-2 and e-3.
TTFM, frequency, amount, and group are all influ-
ential splitters in these models.
Neurology  3
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
Figure 1 Classification and Regression Tree (CART) advanced analysis investigating interactions between dose and patient characteristics
and odds of a favorable outcome (modified Rankin Scale [mRS] 0–2)
Time to first mobilization, median daily number of out-of-bed sessions per day (frequency), median daily out-of-bed activity session time (amount), age (in
years), and stroke severity (NIH Stroke Scale [NIHSS]). Frequency is derived from nursing and physiotherapist data. Amount (minutes) is derived from phys-
iotherapist data only. CI 5 confidence interval.
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DISCUSSION We found a consistent pattern of asso-
ciation between the odds of experiencing little or no
disability (mRS 0–2) at 3 months and the
intervention characteristics irrespective of treatment
group. In particular, we saw 13% improvement in the
odds of a favorable outcome with each additional ses-
sion of out-of-bed activity per day (keeping the time
to first mobilization and daily amount constant).
Conversely, increasing the amount of time spent in
out-of-bed activity, keeping the frequency and time
to first mobilization constant, reduced the odds of a
favorable outcome. The potentially beneficial effect of
increasing the frequency of out-of-bed activity (but
not the amount) was consistent across most of the
efficacy and safety analyses.
These findings begin to unpack the primary re-
sults, where we reported that VEM (very early, fre-
quent, and higher-dose out-of-bed activity) reduced
the odds of a favorable outcome at 3 months.1 This
dose-response analysis suggests that increased fre-
quency of mobilization (keeping other intervention
characteristics constant) helps reduce disability and
increases the odds of walking by 3 months and re-
duces the odds of death. However, increasing
the minutes of out-of-bed activity was more likely
to result in worse outcomes. In other words, these
findings indicate that short, frequent sessions may
be preferable for many patients in the first weeks after
stroke.
Addition of the CART analyses provided further
support for the important influence of session fre-
quency on outcome. Even with the inclusion of
patient characteristics considered strongly predictive
of outcome after stroke (such as stroke severity and
age), intervention characteristics played an explicit
and important role, defining homogenous groups of
patients based on their chances of achieving the favor-
able outcome. Indeed, in patients with more severe
stroke (NIHSS . 13.5), a more favorable outcome
was evident in those with more rather than less ses-
sions (figure e-3). In humans and animals, there is
limited discussion about the potential effect of fre-
quency of intervention on stroke outcome. Recently,
Bell et al.14 studied skilled reaching in stroke-affected
mice and found that twice daily, higher-dose training
accelerated recovery and improved final outcome
compared to a once-a-day, lower-dose regimen. In
humans, a number of systematic reviews and meta-
analyses suggest a dose-response relationship, with
more intensive therapy resulting in improved func-
tional outcome after stroke.5,6,15 Definitions for ther-
apy intensity vary, but to date the focus has been on
amount (minutes) rather than frequency (repetitions
of a task, or sessions per day).16 Generally, inadequate
reporting of therapy interventions, together with sig-
nificant heterogeneity in the timing, amount, fre-
quency, and intensity of training provided,
complicates messaging of poststroke therapy, partic-
ularly in the first few weeks, where few studies exist.17
Table 1 Baseline characteristics of all patients
All patients (n 5 2,104)
Recruitment region, n (%)
Australia/New Zealand 1,243 (59)
Asia 251 (12)
United Kingdom 610 (29)
Patient details
Age, y, median (IQR) 72.5 (62.9–80.3)
Female 818 (40)
Risk factors, n (%)
Hypertension 1,424 (68)
Ischemic heart disease 487 (23)
Hypercholesterolemia 929 (40)
Diabetes mellitus 467 (22)
Atrial fibrillation 466 (22)
Smoking, n (%)
Never smoked 945 (45)
Smokera 431 (20)
Ex-smokerb 693 (33)
Unknown 35 (2)
Living arrangement at time of admission
Home alone/with someone, n (%) 532 (25)/1,542 (73)
Time (in hours) to randomization, median (IQR) 18.2 (12.3–21.8)
First stroke, n (%) 1,721 (82)
NIHSS score
Median (IQR) 7 (4–12)
Mild (NIHSS 1–7), n (%) 1,170 (56)
Moderate (NIHSS 8–16), n (%) 643 (31)
Severe (NIHSS > 16), n (%) 291 (14)
Stroke type (Oxfordshire Stroke Classification), n (%)
TACI 456 (22)
PACI 668 (32)
POCI 199 (9)
LACI 523 (25)
ICH 258 (12)
Treated with rtPA 507 (24)
Baseline walking (MSAS), n (%)
Independent 855 (41)
Supervised or assisted 1,060 (50)
Abbreviations: ICH 5 intracerebral hemorrhage; IQR 5 interquartile range; LACI 5 lacunar
infarct; mRS 5 modified Rankin Scale; MSAS 5 Mobility Scale for Acute Stroke13 walking
score; NIHSS 5 NIH Stroke Scale; PACI 5 partial anterior circulation infarct; POCI 5 pos-
terior circulation infarct; rtPA 5 recombinant tissue plasminogen activator; TACI 5 total
anterior circulation infarct.
a Current smoker, or quitting in the last 2 years.
bQuitting .2 years ago.
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Interestingly, a 3-arm early rehabilitation trial testing
upper limb constraint regimens, although small (n 5
52), also found that a higher amount of training was
inferior to lower-dose usual care.18 A critical challenge
in rehabilitation is determining who should be tar-
geted and when and what is the optimal
intervention.19
The influence of time to first mobilization was less
clear, partly due to a compact distribution pattern
with the median time (IQR) less than 24 hours
(14.7–23.8). The optimal time to commence out-
of-bed activity remains unknown. While early animal
studies showed that very-high-dose training within
the first days poststroke increased brain lesion vol-
ume,20 our recent animal meta-analysis21 found that
a shorter interval between stroke and exercise start
reduced infarct volume (effect size 20.24, 95% CI
20.36 to 20.06, p , 0.004), without significantly
influencing behavioral outcomes.21 A further animal
systematic review showed that early initiated (24–48
hours poststroke) moderate exercise reduced lesion
volume and protected perilesional tissue against oxi-
dative damage and inflammation.22 Given that animal
research to date suggests that activity within 24–48
hours of ischemic stroke onset may be helpful, an
obvious translation gap exists.
Study strengths include that the dose-response
analysis was prespecified11 to help understand our
complex intervention, and we had a strong focus on
the quality of the nurse and physiotherapy data
collected in the trial.11 Our main limitation is that
this exploratory analysis is not an RCT testing each of
the intervention components separately (time,
amount, frequency). Our results will need to be
confirmed in further RCTs. Because we recorded
physiotherapist-assisted out-of-bed therapy time
only (not nursing), these data underestimate the
actual minutes each day that a patient spent under-
taking out-of-bed activity.
Table 3 Effect of intervention characteristics on favorable outcome (mRS 0–2) and unassisted walking
Efficacy
Favorable outcome (mRS 0–2) Walking unassisted 50 meters
OR (95% CI) p Value Binary OR (95% CI) p Value Cox hazard ratio (95% CI) p Value
Model 1
Time to first mobilization
(per extra hour)
0.99 (0.98–1.0) 0.036 1.0 (0.99–1.0) 0.40 0.99 (0.98–0.99) ,0.001
Frequency, median daily sessionsa
(per one extra session)
1.13 (1.09–1.18) ,0.001 1.66 (1.53–1.80) ,0.001 1.10 (1.09–1.13) ,0.001
Daily amount, median
(per extra 5 minutes)
0.94 (0.91–0.97) ,0.001 0.85 (0.81–0.89) ,0.001 0.96 (0.94–0.97) ,0.001
Model 2
Time to first mobilization
(per extra hour)
0.99 (0.98–1.0) 0.025 1.0 (0.99–1.0) 0.48 0.99 (0.98–0.99) ,0.001
Frequency, median daily sessionsa
(per one extra session)
1.14 (1.10–1.18) ,0.001 1.63 (1.51–1.76) ,0.001 1.11 (1.10–1.13) ,0.001
Total amountb (per extra 5 minutes
over intervention period)
0.99 (0.98–0.99) ,0.001 0.98 (0.98–0.99) ,0.001 0.99 (0.99–0.99) ,0.001
Abbreviations: CI 5 confidence interval; mRS 5 modified Rankin Scale; OR 5 odds ratio.
All analyses are adjusted for age and baseline NIH Stroke Scale score. Two models are shown. Model 1 includes examination of the effect of an extra
5 minutes of out-of-bed activity per day, while model 2 includes examination of the effect of an extra 5 minutes of out-of-bed activity over the intervention
period to account for differences in length of hospital stay. Binary OR refers to walking 50 meters at 3 months vs not walking 50 meters at 3 months. That
is, one extra session leads to fewer days required to walking 50 meters, while an extra 5 minutes daily session time is associated with more days to walking
50 meters.
a Frequency is derived from nursing and physiotherapist data.
bAmount (minutes) is derived from physiotherapist data only.
Table 2 Intervention summary, all patients
Characteristics All patients (n 5 2,104), median (IQR)
Time to first mobilization, h 20.2 (14.7–23.8); n 5 2,078; missinga 5 26
Frequency per personb (median daily
sessions of out-of-bed activity)
5 (3–8)
Daily amount per personc (median
minutes per day spent in out-of-bed activity)
17.5 (6–35)
Total amount per personc (minutes over
the intervention periodd)
120 (50–235)
Abbreviation: IQR 5 interquartile range.
Median estimates include days when time or number of out-of-bed sessions 5 0; i.e., the
patient was recorded as not getting up on that day.
aMissing: Hours to first mobilization (n5 26); these patients were never mobilized, due to an
early serious adverse event (n 5 13), decision to palliate (n 5 5), or early death (n 5 5),
transfer from the stroke unit (n 5 1), or drop-out (n 5 1). For these patients, therapy and
nurse recording forms were completed throughout their stroke unit stay, with zero time and
zero sessions.
b Frequency is derived from nursing and physiotherapist data.
c Amount (minutes) is derived from physiotherapist data only.
d Total amount of out-of-bed activity over the intervention period was estimated over the
total length of stay or until 14 days poststroke (whichever occurred first).
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One could argue that the intervention protocol
influenced our findings because intervention dose
was greater when participants had a less severe stroke.
However, given that we found the same relationship
between time to first mobilization, frequency, and
amount of time in the usual care group alone as found
for the whole group, this seems unlikely. That is,
more frequent sessions (keeping mobilization time
and median minutes of out-of-bed activity per day
constant) improved the odds of a good outcome by
12% (OR 1.12, 95% CI 1.04–1.21, p , 0.004).
Interestingly, less time to first mobilization was also
associated with improved odds of a good outcome
(OR 0.98, 95% CI 0.97–0.99, p 5 0.002), while
more minutes of out-of-bed activity was not (table
e-1). Therefore, while the intervention protocol itself
may have confounded some of this association, the
results provide us with important clues on how the
components of early and intensive rehabilitation
affect outcome.
These results provide insights into the drivers of
outcome and provide clinicians with a guide to early
rehabilitation practices. There are 3 important mes-
sages from our results. The first is that physiothera-
pist- and nurse-facilitated mobility interventions
delivered in the acute phase of care can change a pa-
tient’s long-term outcomes, so it is critical that tria-
lists carefully define and measure these interventions.
Second, these results suggest that the frequency of
intervention may be a more important driver of out-
come. This has received little attention to date and
requires further evaluation in future trials. The final
message is that the currently accepted philosophy of
“more practice is always better” needs to be reconsid-
ered, particularly within the first days after stroke.
The issue of timing, frequency, and amount of ther-
apy is more complex that previously realized. This
represents fertile ground for future research.
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Table 4 Effect of intervention characteristics on death and nonfatal serious adverse events
Safety
Deaths Nonfatal SAEs
Fatal or nonfatal
neurologic SAEs
Fatal or nonfatal
immobility SAEs
Binary OR (95% CI) p Value IRR (95% CI) p Value IRR (95% CI) p Value IRR (95% CI) p Value
Model 1
Time to first mobilization
(per extra hour)
0.99 (0.98–1.00) 0.07 1.0 (0.99–1.00) 0.71 1.0 (0.99–1.00) 0.45 1.00 (0.99–1.00) 0.59
Frequency, median daily sessionsa
(per one extra session)
0.78 (0.70–0.88) ,0.01 0.99 (0.95–1.03) 0.55 0.89 (0.84–0.95) 0.001 0.94 (0.87–1.01) 0.11
Daily amount, medianb
(per extra 5 minutes)
0.96 (0.89–1.04) 0.30 0.96 (0.93–0.99) 0.01 1.03 (0.99–1.08) 0.17 0.94 (0.89–1.00) 0.06
Model 2
Time to first mobilization
(per extra hour)
0.99 (0.98–1.00) 0.07 0.99 (0.99–1.00) 0.81 1.00 (0.99–1.00) 0.35 1.00 (0.99–1.00) 0.59
Frequency, median daily sessionsa
(per one extra session)
0.79 (0.71–0.88) ,0.01 0.96 (0.93–0.99) 0.02 0.93 (0.88–0.98) ,0.01 0.91 (0.85–0.97) ,0.01
Total amountb (per extra 5 minutes
over intervention period)
0.99 (0.98–1.00) 0.06 1.00 (1.00–1.00) 0.49 1.00 (0.99–1.00) 0.32 1.0 (0.99–1.00) 0.41
Abbreviations: CI 5 confidence interval; IRR 5 incident rate ratio; OR 5 odds ratio; SAE 5 serious adverse event.
All analyses are adjusted for age and baseline NIH Stroke Scale score. Two models are shown. Model 1 includes examination of the effect of an extra
5 minutes of out-of-bed activity per day, while model 2 includes examination of the effect of an extra 5 minutes of out-of-bed activity over the intervention
period to account for differences in length of hospital stay. Immobility-related SAEs included deep vein thrombosis, pulmonary embolism, pressure sores,
pneumonia, and urinary tract infection. Neurologic SAEs include stroke progression and recurrent stroke.
a Frequency is derived from nursing and physiotherapist data.
bAmount (minutes) is derived from physiotherapist data only.
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